The impact of bortezomib on the risk of thrombosis in multiple myeloma

Leukemia Research

Volumn 35, Issue 2, 2011, Pages 145-146

  Connolly, Gregory ^a  

^a STRONG MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 8; BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; THALIDOMIDE; THROMBIN; THROMBOPLASTIN; WARFARIN;

BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; EDITORIAL; FIBRINOLYSIS; HIGH RISK PATIENT; HUMAN; MULTIPLE MYELOMA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS; THROMBOSIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HUMANS; MULTIPLE MYELOMA; PYRAZINES; RISK FACTORS; THROMBOSIS;

EID: 78751705496     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.09.017     Document Type: Editorial

References (35)

1. Blom J.W., et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005, 293(6):715-722.
2. Heit J.A., et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002, 162(11):1245-1248.
3. Stein P.D., et al. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006, 119(1):60-68.
4. Heit J.A., et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000, 160(6):809-815.
5. Imberti D., et al. Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. Haematologica 2008, 93(2):273-278.
6. Prandoni P., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002, 100(10):3484-3488.
7. Khorana A.A., Connolly G.C. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 2009, 27(29):4839-4847.
8. Khorana A.A., et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008, 111(10):4902-4907.
9. Connolly G.C., et al. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res 2010, 126(2):113-118.
10. Ay C., et al. D-dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009, 27(25):4124-4129.
11. Ay C., et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008, 112(7):2703-2708.
12. Ay C., Pabinger I. Tests predictive of thrombosis in cancer. Thromb Res 2010, 125(Suppl. 2):S12-S15.
13. Kristinsson S.Y., et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood 2010, 115(24):4991-4998.
14. Libourel E.J., et al. High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood 2010, 116(1):22-26.
15. Dimopoulos M., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007, 357(21):2123-2132.
16. Facon T., et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007, 370(9594):1209-1218.
17. Bennett C.L., et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 2006, 296(21):2558-2560.
18. Falanga A., Marchetti M. Venous thromboembolism in the hematologic malignancies. J Clin Oncol 2009, 27(29):4848-4857.
19. Baz R., et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005, 80(12):1568-1574.
20. Zangari M., et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma 2003, 4(1):32-35.
21. Zonder J.A., et al. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 2006, 108(1):403. author reply 404.
22. San Miguel J.F., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359(9):906-917.
23. Jagannath S., et al. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. Br J Haematol 2009, 146(6):619-626.
24. Palumbo A., et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol 2008, 19(6):1160-1165.
25. Palumbo A., et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 2007, 109(7):2767-2772.
26. Terpos E., et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008, 22(12):2247-2256.
27. Zangari M., et al. Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma. Haematologica 2008, 93(6):953-954.
28. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007, 110(6):1723-1729.
29. Uaprasert N., et al. Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis. Eur J Cancer 2010, 46(10):1790-1799.
30. Wagman L.D., et al. Venous thromboembolic disease. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006, 4(9):838-869.
31. Lyman G.H., et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007, 25(34):5490-5505.
32. Mandala M., Falanga A., Roila F. Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann Oncol 2008, 19(Suppl. 2):pii126-pii127.
33. Palumbo A., et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006, 367(9513):825-831.
34. Zangari M., et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004, 126(5):715-721.
35. Shen Y., Zhou X., Wang Z., Yang G., Jiang Y., Sun C., et al. Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma. Leuk Res 2011, 35:147-151.